Syntheses, transformations and pharmaceutical applications of kynurenic acid derivatives

Current Medicinal Chemistry

Volumn 16, Issue 36, 2009, Pages 4828-4842

  Fulop F ^a   Szatmari I ^a   Vamos E ^b   Zadori D ^b   Toldi, J ^b   Vecsei L ^b  

^a UNIVERSITY OF SZEGED   (Hungary)

^b UNIVERSITY OF SZEGED   (Hungary)

Author keywords

Diabetes mellitus; Hypertension; Kynurenic acid; Kynurenic acid derivatives; Neurological disorders; Retinal damage; Schizophrenia

Indexed keywords

4 UREA 5,7 CHLORINE KYNURENINE; 5,7 DICHLORINE KYNURENINE; 7 CHLORINE KYNURENINE; ANTICONVULSIVE AGENT; DIPHENYLUREIDO CHLORINE KYNURENINE; ESTER; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 35; GLUCOSAMINE KYNURENINE; HYDROXYL GROUP; KYNURENIC ACID; KYNURENIC ACID DERIVATIVE; KYNURENINE; PROBENECID; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ALLODYNIA; ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; CATARACT; CHEMICAL ANALYSIS; CHEMICAL MODIFICATION; DIABETES MELLITUS; DOSE RESPONSE; DRUG ACTIVITY; DRUG BRAIN LEVEL; DRUG PENETRATION; DRUG STRUCTURE; DRUG SYNTHESIS; EPILEPSY; EPILEPTIC STATE; HUMAN; HUNTINGTON CHOREA; HYPERTENSION; ISCHEMIA; LOW DRUG DOSE; MIGRAINE; MULTIPLE SCLEROSIS; NEUROPATHIC PAIN; NEUROPROTECTION; NONHUMAN; PAIN; PARKINSON DISEASE; RETINA INJURY; REVIEW; SCHIZOPHRENIA; SEIZURE;

DIABETES MELLITUS; HUMANS; ISCHEMIA; KIDNEY FAILURE; KYNURENIC ACID; NEURODEGENERATIVE DISEASES; SCHIZOPHRENIA;

EID: 71949108894     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986709789909602     Document Type: Review

References (124)

1. Rozsa, E.; Robotka, H.; Vecsei, L.; Toldi, J. The Janus-face kynurenic acid. J. Neural. Transm., 2008, 115, 1087-1091
2. Stone, T.W. Kynurenic acid antagonists and kynurenine pathway inhibitors. Expert. Opin. Investig. Drugs, 2001, 10, 633-645
3. Nemeth, H.; Toldi, J.; Vecsei, L. Role of kynurenines in the central and peripheral nervous systems. Curr. Neurovasc. Res., 2005, 2, 249-260 (Pubitemid 40980183)
4. Nemeth, H.; Toldi, J.; Vecsei, L. Kynurenines, Parkinson's disease and other neurodegenerative disorders: preclinical and clinical studies. J. Neural Transm. Suppl., 2006, 285-304. (Pubitemid 44622214)
5. Sas, K.; Robotka, H.; Toldi, J.; Vecsei, L. Mitochondria, metabolic disturbances, oxidative stress and the kynurenine system, with focus on neurodegenerative disorders. J. Neurol. Sci., 2007, 257, 221-239
6. Rajda, C.; Bergquist, J.; Vecsei, L. Kynurenines, redox disturbances and neurodegeneration in multiple sclerosis. J. Neural. Transm. Suppl., 2007, 323-329
7. Giles, G.I.; Collins, C.A.; Stone, T.W.; Jacob, C. Electrochemical and in vitro evaluation of the redox-properties of kynurenine species. Biochem. Biophys. Res. Commun., 2003, 300, 719-724
8. Nemeth, H.; Robotka, H.; Toldi, J.; Vecsei, L. Kynurenins in the central nervous system: recent developments. CNSA Med. Chem., 2007, 7, 45-46 (Pubitemid 46440371)
9. Robotka, H.; Toldi, J.; Vecsei, L. L-kynurenine: metabolism and mechanism of neuroprotection. Future Neurol., 2008, 3, 169-188
10. Gigler, G.; Szenasi, G.; Simo, A.; Levay, G.; Harsing, L.G., Jr.; Sas, K.; Vecsei, L.; Toldi, J. Neuroprotective effect of Lkynurenine sulfate administered before focal cerebral ischemia in mice and global cerebral ischemia in gerbils. Eur. J Pharmacol., 2007, 564, 116-122 (Pubitemid 46946855)
11. Luchowska, E.; Luchowski, P.; Sarnowska, A.; Wielosz, M.; Turski, W.A.; Urbanska, E.M. Endogenous level of kynurenic acid and activities of kynurenine aminotransferases following transient global ischemia in the gerbil hippocampus. Pol. J. Pharmacol., 2003, 55, 443-447
12. Borza, I.; Horvath, C.; Farkas, S.; Nagy, J.; Kolok, S. Kynurenic acid amide derivatives as NR2B receptor antagonists. WO2006010967, 2006,
13. Borza, I.; Kolok, S.; Galgoczy, K.; Gere, A.; Horvath, C.; Farkas, S.; Greiner, I.; Domany, G. Kynurenic acid amides as novel NR2B selective NMDA receptor antagonists. Bioorg. Med. Chem. Lett., 2007, 17, 406-409 (Pubitemid 46073751)
14. Edmont, D.; Rocher, R.; Plisson, C.; Chenault, J. Synthesis and evaluation of quinoline carboxyguanidines as antidiabetic agents. Bioorg. Med. Chem. Lett., 2000, 10, 1831-1834
15. Edmont, D. Chenault, J. 8-Fluoro-4-hydroxy-1H-[1,2,4]triazino [4,5-a]quinoline-1,6(2H)-dione: synthesis and reactivity. J. Heterocyclic Chem., 2003, 40, 789-793
16. Muirhead, K.M.; Botting, N.P. The synthesis of 5-fluorokynurenine and 6-fluorokynurenic acid as metabolic probes. Arkivoc, 2002, iii, 37-45. (Pubitemid 38957357)
17. (a) Harrison, B.L.; Baron, B.M.; Cousino, D.M.; McDonald, I.A. 4- [(Carboxymethyl)oxy]- and 4-[(carboxymethyl)amino]-5,7-dichloroquinoline-2- carboxylic acid: new antagonists of the strychnine-insensitive glycine binding site on the N-methyl-D-aspartate receptor complex. J. Med. Chem., 1990, 33, 3130-2.
18. (b) Heindel, N.D.; Bechara, I.S.; Kennewell, P.D.; Molnar, J.; Ohnmacht, C.J.; Lemke, S.M.; Lemke, T.F. Cyclization of anilineacetylenedicarboxylate adducts. A modified Conrad-Limpach method for the synthesis of potential antimalarials. J. Med. Chem., 1968, 11, 1218-1221
19. Tabakoff, B. Method for treating chronic pain. WO2007044682, 2007.
20. Bonina, F.P.; Arenare, L.; Ippolito, R.; Boatto, G.; Battaglia, G.; Bruno, V.; de, C.P. Synthesis, pharmacokinetics and anticonvulsant activity of 7-chlorokynurenic acid prodrugs. Int. J Pharm., 2000, 202, 79-88.
21. Kato, Y.; Okada, S.; Tomimoto, K.; Mase, T. A facile bromination of hydroxyheteroarenes. Tetrahedron Lett., 2001, 42, 4849-4851
22. Manfredini, S.; Pavan, B.; Vertuani, S.; Scaglianti, M.; Compagnone, D.; Biondi, C.; Scatturin, A.; Tanganelli, S.; Ferraro, L.; Prasad, P.; Dalpiaz, A. Design, synthesis and activity of ascorbic acid prodrugs of nipecotic, kynurenic and diclophenamic acids, liable to increase neurotropic activity. J Med. Chem., 2002, 45, 559-562.
23. Manfredini, S.; Vertuani, S.; Pavan, B.; Vitali, F.; Scaglianti, M.; Bortolotti, F.; Biondi, C.; Scatturin, A.; Prasad, P.; Dalpiaz, A. Design, synthesis and in vitro evaluation on HRPE cells of ascorbic and 6-bromoascorbic acid conjugates with neuroactive molecules. Bioorg. Med. Chem., 2004, 12, 5453-5463
24. Stone, T.W. Development and therapeutic potential of kynurenic acid and kynurenine derivatives for neuroprotection. Trends Pharmacol. Sci., 2000, 21, 149-154
25. Stone, T.W. Inhibitors of the kynurenine pathway. Eur. J. Med. Chem., 2000, 35, 179-186
26. Nichols, A.C.; Yielding, K.L. Anticonvulsant activity of 4-urea-5,7-dichlorokynurenic acid derivatives that are antagonists at the NMDA-associated glycine binding site. Mol. Chem. Neuropathol., 1998, 35, 1-12.
27. Fuvesi, J.; Somlai, C.; Nemeth, H.; Varga, H.; Kis, Z.; Farkas, T.; Karoly, N.; Dobszay, M.; Penke, Z.; Penke, B.; Vecsei, L.; Toldi, J. Comparative study on the effects of kynurenic acid and glucosamine-kynurenic acid. Pharmacol. Biochem. Behav., 2004, 77, 95-102. (Pubitemid 38076985)
28. Zhang, L.; Sun, F.; Li, Y.; Sun, X.; Liu, X.; Huang, Y.; Zhang, L.H.; Ye, X.S.; Xiao, J. Rapid synthesis of iminosugar derivatives for cell-based in situ screening: discovery of "hit" compounds with anticancer activity. ChemMedChem., 2007, 2, 1594-1597
29. Likhosherstov, L.M.; Novikova, O.S.; Zheltova, A.O.; Shibaev, V.N. N-Glycyl-β-glycopyranosyl-amines, derivatives of mono- and disaharides, and their use for the preparation of carboxylic acid glycoconjugates. Russ. Chem. Bull., Int. Ed., 2000, 49, 1454-1459
30. Liu, J.; Numa, M.M.; Liu, H.; Huang, S.J.; Sears, P.; Shikhman, A.R.; Wong, C.H. Synthesis and high-throughput screening of Nacetyl-beta- hexosaminidase inhibitor libraries targeting osteoarthritis. J. Org. Chem., 2004, 69, 6273-6283
31. Brik, A.; Lin, Y.C.; Elder, J.; Wong, C.H. A quick diversity-oriented amide-forming reaction to optimize P-subsite residues of HIV protease inhibitors. Chem. Biol., 2002, 9, 891-896
32. Tossi, A.; Benedetti, F.; Norbedo, S.; Skrbec, D.; Berti, F.; Romeo, D. Small hydroxyethylene-based peptidomimetics inhibiting both HIV-1 and C. albicans aspartic proteases. Bioorg. Med. Chem., 2003, 11, 4719-4727 (Pubitemid 37230128)
33. Bryant, J.; Buckman, B.; Islam, I.; Mohan, R.; Morrissey, M.; Wei, G.P.; Xu, W. 2-Aminocarbonyl-quinoline compounds as platelet adenosine diphosphate receptor antagonists. WO2004052366, 2004,
34. Knyihar-Csillik, E.; Mihaly, A.; Krisztin-Peva, B.; Robotka, H.; Szatmari, I.; Fulop, F.; Toldi, J.; Csillik, B.; Vecsei, L. The kynurenate analog SZR-72 prevents the nitroglycerol-induced increase of c-fos immunoreactivity in the rat caudal trigeminal nucleus: comparative studies of the effects of SZR-72 and kynurenic acid. Neurosci. Res., 2008, 61, 429-432
35. Vecsei, L.; Boros, M.; Kaszaki, J.; Fulop, F.; Toldi, J.; Szatmari, I. Use of kynurenic acid and derivatives thereof in the treatment of conditions of the gastrointestinal tract accompanied by hypermotility and inflammation or gout or multiple sclerosis. WO2008087461, 2008,
36. Guidetti, P.; Amori, L.; Sapko, M.T.; Okuno, E.; Schwarcz, R. Mitochondrial aspartate aminotransferase: a third kynurenate-producing enzyme in the mammalian brain. J. Neurochem., 2007, 102, 103-111 (Pubitemid 46906272)
37. Guidetti, P.; Okuno, E.; Schwarcz, R. Characterization of rat brain kynurenine aminotransferases I and II. J. Neurosci. Res., 1997, 50, 457-465 (Pubitemid 27488325)
38. Okuno, E.; Nakamura, M.; Schwarcz, R. Two kynurenine aminotransferases in human brain. Brain Res., 1991, 542, 307-312
39. Schmidt, W.; Guidetti, P.; Okuno, E.; Schwarcz, R. Characterization of human brain kynurenine aminotransferases using [3H]kynurenine as a substrate. Neuroscience, 1993, 55, 177-184 (Pubitemid 23194995)
40. Yu, P.; Li, Z.; Zhang, L.; Tagle, D.A.; Cai, T. Characterization of kynurenine aminotransferase III, a novel member of a phylogenetically conserved KAT family. Gene, 2006, 365, 111-118 (Pubitemid 43185231)
41. Ceresoli-Borroni, G.; Guidetti, P.; Schwarcz, R. Acute and chronic changes in kynurenate formation following an intrastriatal quinolinate injection in rats. J. Neural. Transm., 1999, 106, 229-242
42. Guillemin, G.J.; Cullen, K.M.; Lim, C.K.; Smythe, G.A.; Garner, B.; Kapoor, V.; Takikawa, O.; Brew, B.J. Characterization of the kynurenine pathway in human neurons. J. Neurosci., 2007, 27, 12884-12892
43. Stazka, J.; Luchowski, P.; Wielosz, M.; Kleinrok, Z.; Urbanska, E.M. Endothelium-dependent production and liberation of kynurenic acid by rat aortic rings exposed to L-kynurenine. Eur. J. Pharmacol., 2002, 448, 133-137
44. Stazka, J.; Luchowski, P.; Urbanska, E.M. Homocysteine, a risk factor for atherosclerosis, biphasically changes the endothelial production of kynurenic acid. Eur. J. Pharmacol., 2005, 517, 217-223
45. Erhardt, S.; Schwieler, L.; Emanuelsson, C.; Geyer, M. Endogenous kynurenic acid disrupts prepulse inhibition. Biol. Psychiatry, 2004, 56, 255-260 (Pubitemid 39092940)
46. Birch, P.J.; Grossman, C.J.; Hayes, A.G. Kynurenic acid antagonises responses to NMDA via an action at the strychnine-insensitive glycine receptor. Eur. J. Pharmacol., 1988, 154, 85-87
47. Kessler, M.; Terramani, T.; Lynch, G.; Baudry, M. A glycine site associated with N-methyl-D-aspartic acid receptors: characterization and identification of a new class of antagonists. J. Neurochem., 1989, 52, 1319-1328 (Pubitemid 19085960)
48. Parsons, C.G.; Danysz, W.; Quack, G.; Hartmann, S.; Lorenz, B.; Wollenburg, C.; Baran, L.; Przegalinski, E.; Kostowski, W.; Krzascik, P.; Chizh, B.; Headley, P.M. Novel systemically active antagonists of the glycine site of the N-methyl-D-aspartate receptor: electrophysiological, biochemical and behavioral characterization. J. Pharmacol. Exp. Ther., 1997, 283, 1264-1275
49. Bertolino, M.; Vicini, S.; Costa, E. Kynurenic acid inhibits the activation of kainic and N-methyl-D-aspartic acid-sensitive ionotropic receptors by a different mechanism. Neuropharmacology, 1989, 28, 453-457 (Pubitemid 19131677)
50. Stone, T.W;. Connick, J.H. Quinolinic acid and other kynurenines in the central nervous system. Neuroscience, 1985, 15, 597-617. (Pubitemid 15236335)
51. Prescott, C.; Weeks, A.M.; Staley, K.J.; Partin, K.M. Kynurenic acid has a dual action on AMPA receptor responses. Neurosci. Lett., 2006, 402, 108-112
52. Hilmas, C.; Pereira, E.F.; Alkondon, M.; Rassoulpour, A.; Schwarcz, R.; Albuquerque, E.X. The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications. J. Neurosci., 2001, 21, 7463-7473
53. Marchi, M.; Risso, F.; Viola, C.; Cavazzani, P.; Raiteri, M. Direct evidence that release-stimulating alpha7 nicotinic cholinergic receptors are localized on human and rat brain glutamatergic axon terminals. J. Neurochem., 2002, 80, 1071-1078 (Pubitemid 34809959)
54. Rassoulpour, A.; Wu, H.Q.; Ferre, S.; Schwarcz, R. Nanomolar concentrations of kynurenic acid reduce extracellular dopamine levels in the striatum. J. Neurochem., 2005, 93, 762-765 (Pubitemid 40617635)
55. Wang, J.; Simonavicius, N.; Wu, X.; Swaminath, G.; Reagan, J.; Tian, H.; Ling, L. Kynurenic acid as a ligand for orphan G protein-coupled receptor GPR35. J. Biol. Chem., 2006, 281, 22021-22028 (Pubitemid 44181906)
56. Fukui, S.; Schwarcz, R.; Rapoport, S.I.; Takada, Y.; Smith, Q.R. Blood-brain barrier transport of kynurenines: implications for brain synthesis and metabolism. J. Neurochem., 1991, 56, 2007-2017
57. Vecsei, L.; Beal, M.F. Comparative behavioral and pharmacological studies with centrally administered kynurenine and kynurenic acid in rats. Eur. J. Pharmacol., 1991, 196, 239-246
58. Schmitt, M.L.; Graeff, F.G.; Carobrez, A.P. Anxiolytic effect of kynurenic acid microinjected into the dorsal periaqueductal gray matter of rats placed in the elevated plus-maze test. Braz. J. Med. Biol. Res., 1990, 23, 677-679
59. Vecsei, L. Beal, M.F. Intracerebroventricular injection of kynurenic acid, but not kynurenine, induces ataxia and stereotyped behavior in rats. Brain Res. Bull., 1990, 25, 623-627
60. Smith, D.H.; Okiyama, K.; Thomas, M.J.; McIntosh, T.K. Effects of the excitatory amino acid receptor antagonists kynurenate and indole-2-carboxylic acid on behavioral and neurochemical outcome following experimental brain injury. J. Neurosci., 1993, 13, 5383-5392
61. Lewen, A.; Matz, P.; Chan, P.H. Free radical pathways in CNS injury. J. Neurotrauma, 2000, 17, 871-890
62. Guillemin, G.J.; Meininger, V.; Brew, B.J. Implications for the kynurenine pathway and quinolinic acid in amyotrophic lateral sclerosis. Neurodegener. Dis., 2005, 2, 166-176 (Pubitemid 43827918)
63. Baran, H.; Jellinger, K.; Deecke, L. Kynurenine metabolism in Alzheimer's disease. J. Neural Transm., 1999, 106, 165-181
64. Ogawa, T.; Matson, W.R.; Beal, M.F.; Myers, R.H.; Bird, E.D.; Milbury, P.; Saso, S. Kynurenine pathway abnormalities in Parkinson's disease. Neurology, 1992, 42, 1702-1706
65. Beal, M.F.; Matson, W.R.; Swartz, K.J.; Gamache, P.H.; Bird, E.D. Kynurenine pathway measurements in Huntington's disease striatum: evidence for reduced formation of kynurenic acid. J. Neurochem., 1990, 55, 1327-1339 (Pubitemid 20306037)
66. Jauch, D.; Urbanska, E.M.; Guidetti, P.; Bird, E.D.; Vonsattel, J.P.; Whetsell, W.O., Jr.; Schwarcz, R. Dysfunction of brain kynurenic acid metabolism in Huntington's disease: focus on kynurenine aminotransferases. J. Neurol. Sci., 1995, 130, 39-47.
67. Guidetti, P.; Luthi-Carter, R.E.; Augood, S.J.; Schwarcz, R. Neostriatal and cortical quinolinate levels are increased in early grade Huntington's disease. Neurobiol. Dis., 2004, 17, 455-461
68. Rejdak, K.; Bartosik-Psujek, H.; Dobosz, B.; Kocki, T.; Grieb, P.; Giovannoni, G.; Turski, W.A.; Stelmasiak, Z. Decreased level of kynurenic acid in cerebrospinal fluid of relapsing-onset multiple sclerosis patients. Neurosci. Lett., 2002, 331, 63-65 (Pubitemid 35279383)
69. Rejdak, K.; Petzold, A.; Kocki, T.; Kurzepa, J.; Grieb, P.; Turski, W.A.; Stelmasiak, Z. Astrocytic activation in relation to inflammatory markers during clinical exacerbation of relapsing-remitting multiple sclerosis. J. Neural. Transm., 2007, 114, 1011-1015
70. Yamamoto, H.; Murakami, H.; Horiguchi, K.; Egawa, B. Studies on cerebrospinal fluid kynurenic acid concentrations in epileptic children. Brain Dev., 1995, 17, 327-329
71. Heyes, M.P.; Saito, K.; Devinsky, O.; Nadi, N.S. Kynurenine pathway metabolites in cerebrospinal fluid and serum in complex partial seizures. Epilepsia, 1994, 35, 251-257
72. Schwarcz, R.; Rassoulpour, A.; Wu, H.Q.; Medoff, D.; Tamminga, C.A.; Roberts, R.C. Increased cortical kynurenate content in schizophrenia. Biol. Psychiatry, 2001, 50, 521-530
73. Erhardt, S.; Schwieler, L.; Nilsson, L.; Linderholm, K.; Engberg, G. The kynurenic acid hypothesis of schizophrenia. Physiol. Behav., 2007, 92, 203-209
74. Zarnowski, T.; Rejdak, R.; Zielinska-Rzecka, E.; Zrenner, E.; Grieb, P.; Zagorski, Z.; Junemann, A.; Turski, W.A. Elevated concentrations of kynurenic acid, a tryptophan derivative, in dense nuclear cataracts. Curr. Eye Res., 2007, 32, 27-32.
75. Dohmen, C.; Kumura, E.; Rosner, G.; Heiss, W.D.; Graf, R. Extracellular correlates of glutamate toxicity in short-term cerebral ischemia and reperfusion: a direct in vivo comparison between white and gray matter. Brain Res., 2005, 1037, 43-51. (Pubitemid 40362380)
76. Salvati, P.; Ukmar, G.; Dho, L.; Rosa, B.; Cini, M.; Marconi, M.; Molinari, A.; Post, C. Brain concentrations of kynurenic acid after a systemic neuroprotective dose in the gerbil model of global ischemia. Prog. Neuropsychopharmacol. Biol. Psychiatry, 1999, 23, 741-752 (Pubitemid 29268417)
77. Sas, K.; Csete, K.; Vecsei, L.; Papp, J.G. Effect of systemic administration of L-kynurenine on corticocerebral blood flow under normal and ischemic conditions of the brain in conscious rabbits. J. Cardiovasc. Pharmacol., 2003, 42, 403-409
78. Robotka, H.; Sas, K.; Agoston, M.; Rozsa, E.; Szenasi, G.; Gigler, G.; Vecsei, L.; Toldi, J. Neuroprotection achieved in the ischaemic rat cortex with L-kynurenine sulphate. Life Sci., 2008, 82, 915-919
79. Sas, K.; Robotka, H.; Rozsa, E.; Agoston, M.; Szenasi, G.; Gigler, G.; Marosi, M.; Kis, Z.; Farkas, T.; Vecsei, L.; Toldi, J. Kynurenine diminishes the ischemia-induced histological and electrophysiological deficits in the rat hippocampus. Neurobiol. Dis., 2008, 32, 302-308
80. Widner, B.; Leblhuber, F.; Walli, J.; Tilz, G.P.; Demel, U.; Fuchs, D. Tryptophan degradation and immune activation in Alzheimer's disease. J. Neural. Transm., 2000, 107, 343-353 (Pubitemid 30162696)
81. Widner, B.; Leblhuber, F.; Fuchs, D. Increased neopterin production and tryptophan degradation in advanced Parkinson's disease. J. Neural. Transm., 2002, 109, 181-189 (Pubitemid 34185664)
82. Ossowska, K.; Lorenc-Koci, E.; Konieczny, J.; Wolfarth, S. The role of striatal glutamate receptors in models of Parkinson's disease. Amino. Acids, 1998, 14, 11-15 (Pubitemid 28051145)
83. Stoy, N.; Mackay, G.M.; Forrest, C.M.; Christofides, J.; Egerton, M.; Stone, T.W.; Darlington, L.G. Tryptophan metabolism and oxidative stress in patients with Huntington's disease. J. Neurochem., 2005, 93, 611-623 (Pubitemid 40617621)
84. Sapko, M.T.; Guidetti, P.; Yu, P.; Tagle, D.A.; Pellicciari, R.; Schwarcz, R. Endogenous kynurenate controls the vulnerability of striatal neurons to quinolinate: Implications for Huntington's disease. Exp. Neurol., 2006, 197, 31-40. (Pubitemid 41817219)
85. Hartai, Z.; Klivenyi, P.; Janaky, T.; Penke, B.; Dux, L.; Vecsei, L. Kynurenine metabolism in multiple sclerosis. Acta Neurol. Scand., 2005, 112, 93-96
86. Amirkhani, A.; Rajda, C.; Arvidsson, B.; Bencsik, K.; Boda, K.; Seres, E.; Markides, K.E.; Vecsei, L.; Bergquist, J. Interferon-beta affects the tryptophan metabolism in multiple sclerosis patients. Eur. J. Neurol., 2005, 12, 625-631 (Pubitemid 41117289)
87. Nemeth, H.; Robotka, H.; Kis, Z.; Rozsa, E.; Janaky, T.; Somlai, C.; Marosi, M.; Farkas, T.; Toldi, J.; Vecsei, L. Kynurenine administered together with probenecid markedly inhibits pentylenetetrazol-induced seizures. An electrophysiological and behavioural study. Neuropharmacology, 2004, 47, 916-925 (Pubitemid 39440985)
88. Vecsei, L.; Miller, J.; MacGarvey, U.; Beal, M.F. Kynurenine and probenecid inhibit pentylenetetrazol- and NMDLA-induced seizures and increase kynurenic acid concentrations in the brain. Brain Res. Bull., 1992, 28, 233-238
89. Kaminski, R.M.; Zielinska, E.; Dekundy, A.; van, L.G.; Turski, W. Deficit of endogenous kynurenic acid in the frontal cortex of rats with a genetic form of absence epilepsy. Pol. J. Pharmacol., 2003, 55, 741-746 (Pubitemid 37540873)
90. Scharfman, H.E.; Hodgkins, P.S.; Lee, S.C.; Schwarcz, R. Quantitative differences in the effects of de novo produced and exogenous kynurenic acid in rat brain slices. Neurosci. Lett., 1999, 274, 111-114 (Pubitemid 29457452)
91. Kocki, T.; Wielosz, M.; Turski, W.A.; Urbanska, E.M. Enhancement of brain kynurenic acid production by anticonvulsants - novel mechanism of antiepileptic activity? Eur. J. Pharmacol., 2006, 541, 147-151
92. Wu, H.Q.; Lee, S.C.; Scharfman, H.E.; Schwarcz, R. L-4-chlorokynurenine attenuates kainate-induced seizures and lesions in the rat. Exp. Neurol., 2002, 177, 222-232 (Pubitemid 35356835)
93. Wu, H.Q.; Rassoulpour, A.; Goodman, J.H.; Scharfman, H.E.; Bertram, E.H.; Schwarcz, R. Kynurenate and 7-chlorokynurenate formation in chronically epileptic rats. Epilepsia, 2005, 46, 1010-1016 (Pubitemid 40962145)
94. Battaglia, G.; La, R.M.; Bruno, V.; Arenare, L.; Ippolito, R.; Copani, A.; Bonina, F.; Nicoletti, F. Systemically administered Dglucose conjugates of 7-chlorokynurenic acid are centrally available and exert anticonvulsant activity in rodents. Brain Res., 2000, 860, 149-156 (Pubitemid 30155848)
95. Robotka, H.; Nemeth, H.; Somlai, C.; Vecsei, L.; Toldi, J. Systemically administered glucosamine-kynurenic acid, but not pure kynurenic acid, is effective in decreasing the evoked activity in area CA1 of the rat hippocampus. Eur. J. Pharmacol., 2005, 513, 75-80. (Pubitemid 40692248)
96. Mazarati, A.M.; Wasterlain, C.G. N-methyl-D-asparate receptor antagonists abolish the maintenance phase of self-sustaining status epilepticus in rat. Neurosci. Lett., 1999, 265, 187-190
97. Sierra-Paredes, G.; Senra-Vidal, A.; Sierra-Marcuno, G. Effect of extracellular long-time microperfusion of high concentrations of glutamate and glycine on picrotoxin seizure thresholds in the hippocampus of freely moving rats. Brain Res., 2001, 888, 19-25.
98. Ohtani, K.; Tanaka, H.; Yoneda, Y.; Yasuda, H.; Ito, A.; Nagata, R.; Nakamura, M. In vitro and in vivo antagonistic activities of SM-31900 for the NMDA receptor glycine-binding site. Brain Res., 2002, 944, 165-173 (Pubitemid 34775018)
99. Vikelis, M. Mitsikostas, D.D. The role of glutamate and its receptors in migraine. CNS Neurol. Disord. Drug Targets, 2007, 6, 251-257 (Pubitemid 47232936)
100. Knyihar-Csillik, E.; Chadaide, Z.; Okuno, E.; Krisztin-Peva, B.; Toldi, J.; Varga, C.; Molnar, A.; Csillik, B.; Vecsei, L. Kynurenine aminotransferase in the supratentorial dura mater of the rat: effect of stimulation of the trigeminal ganglion. Exp. Neurol., 2004, 186, 242-247 (Pubitemid 38333197)
101. Knyihar-Csillik, E.; Toldi, J.; Mihaly, A.; Krisztin-Peva, B.; Chadaide, Z.; Nemeth, H.; Fenyo, R.; Vecsei, L. Kynurenine in combination with probenecid mitigates the stimulation-induced increase of c-fos immunoreactivity of the rat caudal trigeminal nucleus in an experimental migraine model. J. Neural. Transm., 2007, 114, 417-421 (Pubitemid 46474855)
102. Jiang, M.; Behbehani, M.M. Physiological characteristics of the projection pathway from the medial preoptic to the nucleus raphe magnus of the rat and its modulation by the periaqueductal gray. Pain, 2001, 94, 139-147
103. Hu, J.Y.; Zhao, Z.Q. Differential contributions of NMDA and non-NMDA receptors to spinal Fos expression evoked by superficial tissue and muscle inflammation in the rat. Neuroscience, 2001, 106, 823-831
104. Alvarez-Vega, M.; Baamonde, A.; Gutierrez, M.; Hidalgo, A.; Menendez, L. Intrathecal N-methyl-D-aspartate (NMDA) induces paradoxical analgesia in the tail-flick test in rats. Pharmacol. Biochem. Behav., 2000, 65, 621-625
105. Zhang, Y.Q.; Ji, G.C.; Wu, G.C.; Zhao, Z.Q. Excitatory amino acid receptor antagonists and electroacupuncture synergetically inhibit carrageenan-induced behavioral hyperalgesia and spinal fos expression in rats. Pain, 2002, 99, 525-535
106. Simone, D.A.; Nolano, M.; Johnson, T.; Wendelschafer-Crabb, G.; Kennedy, W.R. Intradermal injection of capsaicin in humans produces degeneration and subsequent reinnervation of epidermal nerve fibers: correlation with sensory function. J. Neurosci., 1998, 18, 8947-8959
107. Song, X.J.; Zhao, Z.Q. Differential effects of NMDA and non-NMDA receptor antagonists on spinal cutaneous vs muscular nociception in the cat. Neuroreport, 1993, 4, 17-20. (Pubitemid 23066379)
108. Johansen, J.P.; Fields, H.L. Glutamatergic activation of anterior cingulate cortex produces an aversive teaching signal. Nat. Neurosci., 2004, 7, 398-403.
109. Ren, K.; Williams, G.M.; Hylden, J.L.; Ruda, M.A.; Dubner, R. The intrathecal administration of excitatory amino acid receptor antagonists selectively attenuated carrageenan-induced behavioral hyperalgesia in rats. Eur. J. Pharmacol., 1992, 219, 235-243
110. Christoph, T.; Reissmuller, E.; Schiene, K.; Englberger, W.; Chizh, B.A. Antiallodynic effects of NMDA glycine(B) antagonists in neuropathic pain: possible peripheral mechanisms. Brain Res., 2005, 1048, 218-227
111. Erhardt, S.; Blennow, K.; Nordin, C.; Skogh, E.; Lindstrom, L.H.; Engberg, G. Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia. Neurosci. Lett., 2001, 313, 96-98 (Pubitemid 32973903)
112. Erhardt, S.; Engberg, G. Increased phasic activity of dopaminergic neurones in the rat ventral tegmental area following pharmacologically elevated levels of endogenous kynurenic acid. Acta Physiol Scand., 2002, 175, 45-53. (Pubitemid 34534004)
113. Erhardt, S.; Schwieler, L.; Engberg, G. Kynurenic acid and schizophrenia. Adv. Exp. Med. Biol., 2003, 527, 155-165
114. French, E.D. Phencyclidine and the midbrain dopamine system: electrophysiology and behavior. Neurotoxicol. Teratol., 1994, 16, 355-362
115. Stone, T.W.; Forrest, C.M.; Mackay, G.M.; Stoy, N.; Darlington, L.G. Tryptophan, adenosine, neurodegeneration and neuroprotection. Metab. Brain Dis., 2007, 22, 337-352
116. Shepard, P.D.; Joy, B.; Clerkin, L.; Schwarcz, R. Micromolar brain levels of kynurenic acid are associated with a disruption of auditory sensory gating in the rat. Neuropsychopharmacology, 2003, 28, 1454-1462 (Pubitemid 41070880)
117. Zarnowski, T.; Rejdak, R.; Zagorski, Z.; Juenemann, A.G.; Zrenner, E.; Kocki, T.; Urbanska, E.M.; Turski, W.A. Content of kynurenic acid and activity of kynurenine aminotransferases in mammalian eyes. Ophthalmic Res., 2004, 36, 124-128
118. Rejdak, R.; Kohler, K.; Kocki, T.; Shenk, Y.; Turski, W.A.; Okuno, E.; Lehaci, C.; Zagorski, Z.; Zrenner, E.; Schuettauf, F. Age-dependent decrease of retinal kynurenate and kynurenine aminotransferases in DBA/2J mice, a model of ocular hypertension. Vis. Res., 2004, 44, 655-660 (Pubitemid 38125106)
119. Guo, L.; Salt, T.E.; Maass, A.; Luong, V.; Moss, S.E.; Fitzke, F.W.; Cordeiro, M.F. Assessment of neuroprotective effects of glutamate modulation on glaucoma-related retinal ganglion cell apoptosis in vivo. Invest. Ophthalmol. Vis. Sci., 2006, 47, 626-633
120. Levkovitch-Verbin, H.; Quigley, H.A.; Martin, K.R.; Zack, D.J.; Pease, M.E.; Valenta, D.F. A model to study differences between primary and secondary degeneration of retinal ganglion cells in rats by partial optic nerve transection. Invest. Ophthalmol. Vis. Sci., 2003, 44, 3388-3393
121. Rejdak, R.; Zarnowski, T.; Turski, W.A.; Kocki, T.; Zagorski, Z.; Guenther, E.; Kohler, K.; Zrenner, E. Changes of kynurenic acid content in the rat and chicken retina during ontogeny. Graefes Arch. Clin. Exp. Ophthalmol., 2002, 240, 687-691 (Pubitemid 36075631)
122. Hama, Y.; Katsuki, H.; Tochikawa, Y.; Suminaka, C.; Kume, T.; Akaike, A. Contribution of endogenous glycine site NMDA agonists to excitotoxic retinal damage in vivo. Neurosci. Res., 2006, 56, 279-285 (Pubitemid 44572536)
123. Andrzejewska-Buczko, J.; Pawlak, D.; Tankiewicz, A.; Matys, T.; Buczko, W. Possible involvement of kynurenamines in the pathogenesis of cataract in diabetic patients. Med. Sci. Monit., 2001, 7, 742-745 (Pubitemid 32691755)
124. Ito, S.; Komatsu, K.; Tsukamoto, K.; Sved, A.F. Excitatory amino acids in the rostral ventrolateral medulla support blood pressure in spontaneously hypertensive rats. Hypertension, 2000, 35, 413-417